LifeStance Health Group, Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Financial statements are unaudited. Unless noted otherwise, dollar amounts below are in millions; comparisons are with 2022.
Business context
LifeStance operates an outpatient mental health platform offering in-person and virtual psychiatric evaluations, testing and therapy. It reported 6,418 clinicians and 1.7 million patient visits in Q3; nine-month visits were 5.1 million. Revenue is primarily patient-service revenue reimbursed by third-party payors.
Financial performance and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $262.9 | $217.6 | $775.1 | $630.2 |
| Revenue growth | 21% | 25% | 23% | 32% |
| Center costs, excluding D&A | $186.7 | $157.3 | $556.3 | $455.9 |
| General and administrative expenses | $130.9 | $81.2 | $317.4 | $288.2 |
| Loss from operations | $(74.4) | $(38.8) | $(156.9) | $(164.2) |
| Net loss | $(61.6) | $(37.9) | $(141.3) | $(168.9) |
| Adjusted EBITDA (non-GAAP) | $14.6 | $15.4 | $38.8 | $42.5 |
| Operating cash flow | Not provided separately | Not provided separately | $(33.7) | $16.9 |
Margins: Q3 Center Margin was $76.2 million, approximately 29.0% of revenue, versus $60.3 million, or 27.7%, in Q3 2022. Q3 operating margin was approximately (28.3)%, compared with (17.9)%. Adjusted EBITDA margin was approximately 5.5%, versus 7.1%. Center Margin and Adjusted EBITDA are non-GAAP measures.
Balance sheet and debt: Cash and cash equivalents were $42.6 million at September 30, down from $108.6 million at year-end 2022. Patient accounts receivable rose to $149.7 million from $100.9 million. Long-term debt, net, was $248.4 million; total principal outstanding was $257.1 million. The company had no revolving-facility balance at quarter-end and reported compliance with debt covenants. The credit agreement includes a $50 million revolver and delayed-draw commitments. In October, the company drew an additional $8 million under the delayed-draw facility. Non-cancellable future operating lease payments totaled $279.1 million.
Cash flows: Nine-month investing cash outflow was $48.9 million, including $29.1 million of property and equipment purchases and $19.8 million for acquisitions. Financing provided $16.6 million, primarily from $25.0 million of borrowings. Cash declined by $66.0 million over the period.
Material changes and drivers
- Q3 revenue increased 21%, chiefly due to 20% more patient visits, reflecting clinician growth and improved average productivity; modest payor-rate increases also supported revenue. Management attributed the nine-month increase to clinician growth, productivity, prior acquisitions and a 20% rise in visits.
- Q3 center costs rose 19%, slower than revenue growth. In contrast, G&A increased 61%, largely due to professional and legal expenses, including the shareholder lawsuit settlement, as well as higher salaries and real-estate optimization costs.
- Q3 net loss widened despite higher revenue, while nine-month net loss narrowed year over year. Nine-month Adjusted EBITDA declined. Stock-based compensation expense fell materially year over year, but remains a significant expense.
- Operating cash flow turned negative for the first nine months, compared with positive cash flow in 2022. Management said cash declined partly because it held claims for several large payors while seeking rate increases, increasing receivables; it expected to bill most held claims and collect cash by year-end.
Outlook, risks and unusual items
- Management expects revenue growth to continue to be driven by clinician recruiting, de novo centers and more visits, including virtual care. It expects center costs to rise in the short to medium term as it invests in expansion. No numeric revenue, earnings or cash-flow guidance is provided.
- Management believes existing cash will fund operating and capital needs for at least 12 months from the financial-statement issuance date, without additional financing. This assessment depends on assumptions; the filing cautions that additional financing may be needed and may not be available on acceptable terms.
- The company is reducing and optimizing its physical footprint in response to a shift toward virtual visits. It recorded $5.0 million of real-estate optimization charges in the first nine months and expects approximately $10 million for full-year 2023, with approximately $5 million more anticipated in Q4.
- A securities class action settlement of $50 million was preliminarily approved by the court on October 25, 2023. The gross settlement was accrued at September 30; the company expects the settlement and related legal costs to be approximately $50 million net of insurance. Separate employee compensation and website-privacy class actions remain unresolved; the company reported no material accrual for these matters and said losses could not be reasonably estimated.
- Commercial payors represented 91% of revenue. Two commercial payors each accounted for at least 10% of revenue (19% and 13% in Q3), creating payor concentration and reimbursement-rate exposure. Other risks include clinician recruitment and retention, healthcare regulation, affiliated-practice arrangements, competition, data security and debt obligations.
- Management concluded disclosure controls and procedures were ineffective as of September 30 because previously reported material weaknesses in financial reporting controls remained. Remediation was ongoing and not yet considered complete. The company expects to become a large accelerated filer and cease being an emerging growth company in 2024, bringing additional compliance requirements and costs.
Most important facts for investors to verify
- Whether the held payor claims were billed and collected as expected, and whether receivables and operating cash flow improve.
- The settlement’s final court approval, insurance recovery and ultimate net cash cost; developments in the other disclosed lawsuits.
- Whether revenue growth converts to improved operating results, given rising G&A, continued losses and lower year-to-date Adjusted EBITDA.
- Available liquidity, further delayed-draw borrowing, debt service and covenant compliance, particularly as cash was $42.6 million at quarter-end.
- Progress in remediating material weaknesses before the company becomes subject to large-accelerated-filer requirements.